Supriya Lifescience reports robust Q1 FY25 results with 21.7% revenue growth

European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24

Morepen Labs Q1 FY25 profit surges 147% to Rs. 36.17 Cr

Morepen Labs successfully raised Rs. 200 Crore through QIP

Novo Nordisk's H1 sales increased by 24% in Danish kroner

For the 2024 outlook, sales growth is now expected to be 22-28% at CER

HealthCare Global Enterprises posts Q1 FY25 PAT higher at Rs. 12.1 Cr

Our centers are performing as expected or even better

Allergan Aesthetics drives India’s potential in the global aesthetic market

The International Society of Aesthetic Plastic Surgery reported that non-surgical procedures outnumbered surgical ones globally in 2020

Biocon posts Q1 FY25 PAT higher at Rs. 660 Cr

This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.

Bio-economy is going to spearhead India’s future growth story: Dr. Jitendra Singh

AstraZeneca Pharma India achieves 31% revenue growth in Q1 FY25

The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years

JB Pharma records Q1 FY25 PAT higher by 25% to Rs. 177 Cr

Expect the international business including CDMO business to pick-up in the second half of the financial year

Apollo Clinic launches nationwide vaccination campaign to tackle monsoon illnesses

Organization to provide vaccinations & treatments for several monsoon related diseases and illnesses across all 102 clinics